Loading Bonafide Research

Saudi Arabia Radiotherapy Market Overview, 2031

The Saudi Arabia Radiotherapy market is anticipated to add to more than USD 20 Million by 2026–31.

Key Insights


• The Saudi Arabian radiotherapy market operates within a rapidly evolving healthcare system, with significant government investment in advanced cancer care infrastructure aligned with Vision 2030. Cancer rates in the GCC region are projected to rise by over 140% between 2020 and 2040, driving sustained demand for radiation oncology services .
• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, with linear accelerators forming the backbone of treatment delivery. Varian Medical Systems holds an estimated 40–50% of the installed base, followed by Elekta at 30–40% . IMRT and IGRT techniques have been progressively integrated across healthcare facilities nationwide .
• Radiotherapy systems and equipment represent the largest offering segment, with the market entirely import-dependent. The Kingdom has no domestic teletherapy machine manufacturing capability, with equipment sourced from the United States, Europe, and Japan . A standard single-energy linear accelerator with IGRT capabilities typically carries an equipment price of USD 2.0–3.5 million .
• Hospitals and integrated cancer centres are the largest end-user segment, though disparities exist between public and private sectors. A 2024 survey of 17 radiotherapy centres found public and mixed facilities treated a mean of 911 and 2,141 patients annually respectively, compared with 254 patients at private centres . The Central Region, anchored by Riyadh, dominates the market due to the concentration of healthcare infrastructure .
• Regulatory oversight is provided by the Saudi Food and Drug Authority, which mandates technical and clinical specification approval for radioactive medical materials before licensing by the Nuclear and Radiological Regulatory Authority . The Kingdom has emerged as a pioneer in advanced cancer care in the region, with the Saudi Proton Therapy Centre in Riyadh becoming fully operational in December 2023 as the first and only proton beam therapy facility in the Middle East .

Market Outlook


• According to the research report, "Saudi Arabia Radiotherapy Market Overview, 2031," published by Bonafide Research, the Saudi Arabia Radiotherapy market is anticipated to add to more than USD 20 Million by 2026–31. This growth reflects sustained government investment through Vision 2030, expansion of advanced treatment capabilities, and increasing cancer incidence across the Kingdom.
• The market is expected to benefit from continued investment in radiotherapy infrastructure. The Saudi Proton Therapy Centre at King Fahd Medical City represents one of the largest health sector projects, established on an area of 4,000 square metres at a cost exceeding SR 924 million (approximately USD 246 million) . The centre aims to treat about 1,700 patients annually with precise proton beam therapy for complex oncologic cases, eliminating the need for patients to travel abroad for treatment .
• Technology adoption is accelerating through the integration of advanced radiotherapy systems. Varian installed the first Halcyon system in Saudi Arabia in April 2024 at the Batik-X radiation therapy centre in Riyadh, in partnership with BaraSeen Medical Company . The Kingdom is also pioneering in cancer radiopharmaceuticals, with King Faisal Specialist Hospital and Research Centre locally producing essential radionuclides such as iodine-123 and gallium-67, reducing reliance on imports .
• The market is also influenced by workforce and access challenges. A 2024 study published in Frontiers in Oncology found that public and private sector disparities may undermine equitable access to radiotherapy services, with waiting times for radical treatment in public centres requiring policy attention . Training gaps across many centres suggest the need for coordinated national continuing professional development programmes to support safe implementation of advanced technologies .
• Long-term growth is supported by sustained policy commitment. Johns Hopkins Aramco Healthcare unveiled plans for an Oncology Center of Excellence in Riyadh in October 2025, specialising in breast, colorectal, and prostate cancers . Strategic partnerships between the Ministry of Investment, KFSH&RC, and international pharmaceutical companies are advancing integrated cancer treatment approaches combining cell therapy and radiotherapy .

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


Market Dynamics



Driver: Vision 2030 Healthcare Transformation and Infrastructure Investment
The primary driver of the Saudi Arabian radiotherapy market is the Kingdom's comprehensive healthcare transformation under Vision 2030. The Health Sector Transformation Programme is restructuring the Ministry of Health from a provider-regulator into a regulator and strategist, with clinical delivery devolving into regional Health Clusters and Centres of Excellence . This framework has catalysed substantial investment in radiotherapy infrastructure, exemplified by the Saudi Proton Therapy Centre the first and only proton beam therapy facility in the Middle East which became fully operational in December 2023 at a cost exceeding SR 924 million . The centre provides highly targeted radiation therapy particularly effective for tumours in sensitive areas such as the brain, spine, and head and neck, as well as in paediatric oncology . The Kingdom's commitment to healthcare excellence, supported by strategic partnerships with global institutions like Johns Hopkins Medicine, has further bolstered its reputation as a regional healthcare hub, attracting patients seeking specialised treatments and stimulating market demand for radiotherapy services .

Challenge: Import Dependency and Workforce Constraints
A significant challenge facing the Saudi Arabian radiotherapy market is the complete import dependency for teletherapy machines and the structural workforce shortages that constrain service delivery. No Saudi-based manufacturer of teletherapy machines exists, and technological and regulatory barriers to entry remain prohibitive for local production . The Kingdom relies entirely on global OEM supply chains, with typical order-to-delivery lead times of 6–9 months for standard linear accelerators . Additionally, a 2024 survey of 17 radiotherapy centres found that public and mixed facilities treated significantly higher patient volumes (mean of 911 and 2,141 patients/year respectively) compared with private centres (mean of 254 patients/year), indicating capacity and access disparities . The study identified that structural factors including workforce capacity, equipment allocation, training infrastructure, and procurement processes may undermine equitable access to radiotherapy services across the Kingdom . Training gaps across many centres suggest the need for coordinated national continuing professional development programmes rather than relying solely on vendor-based education .

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Trend: Proton Therapy Expansion and Advanced Technology Adoption
A major trend shaping the Saudi Arabian radiotherapy market is the expansion of proton therapy capabilities and the adoption of advanced treatment technologies. The Saudi Proton Therapy Centre, the first facility of its kind in the Middle East, is fully operational and targeting to treat about 1,700 patients annually . The centre features a cyclotron, beam transport system, rotating gantry, five treatment rooms with control rooms, CT simulation room, and radiation planning systems . Proton therapy is particularly indicated when tumours are adjacent to vital organs, when radiation dose exceeds safe levels for organs, and for re-irradiation cases demonstrating clear applications in eye, spinal cord, brain, skull base, liver, paediatric, and sinus tumours . Beyond proton therapy, the Kingdom is advancing integrated cancer treatment approaches. In May 2025, ImmunityBio signed a Memorandum of Understanding with the Ministry of Investment, KFSH&RC, and KAIMRC to launch the FDA-approved "Cancer BioShield" immunotherapy platform in the Middle East, integrating cell therapy and radiotherapy . KFSH&RC is also pioneering CAR-T cell therapy and CRISPR gene editing for cancer treatment, positioning the Kingdom at the forefront of oncology innovation .

Policies


• The Saudi Food and Drug Authority requires technical and clinical specification approval for radioactive medical materials before licensing by the Nuclear and Radiological Regulatory Authority, under Royal Decree No. M/54 (1442 AH) . The approval process for importing radioactive medical materials requires establishment accounts in the electronic MRMR system .
• The Nuclear and Radiological Regulatory Authority issues licences for activities related to the use of radioactive medical materials. Facilities must obtain necessary licences for beneficiary, transporter, and supplier entities before SFDA approval can be granted .
• The Health Sector Transformation Programme under Vision 2030 is restructuring the Ministry of Health into a regulator and strategist, with clinical delivery devolving into regional Health Clusters and Centres of Excellence . The programme names tertiary cancer care as a priority vertical .
• Saudi Arabia's Health Sector Transformation Programme is expanding the universe of specialty drugs that receive formal SFDA registration while simultaneously increasing diagnostic capacity in oncology genomics . This creates sustained demand for radiotherapy services and associated equipment.
• The Saudi Proton Therapy Centre at King Fahd Medical City represents one of the largest health sector projects, established on an area of 4,000 square metres at a cost exceeding SR 924 million, and is the first and only proton beam therapy facility in the Middle East .
• Johns Hopkins Aramco Healthcare, a joint venture between Saudi Aramco and Johns Hopkins Medicine, unveiled plans for an Oncology Center of Excellence in Riyadh in October 2025, specialising in breast, colorectal, and prostate cancers .

Segment Analysis



Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari


Saudi Arabia Radiotherapy Market By Therapy Type
• External Beam Radiotherapy (EBRT): This is the largest therapy segment, supported by an installed base of linear accelerators across public, private, and military healthcare facilities. Varian Medical Systems holds an estimated 40–50% of the installed base, while Elekta accounts for approximately 30–40% . EBRT is versatile and effective, offering precise targeting of tumours with minimal side effects through advanced techniques including IMRT and IGRT . The availability of skilled radiation oncologists, medical physicists, and technologists trained in EBRT further supports its widespread adoption .
• Internal / Brachytherapy: This segment remains clinically established, particularly for gynaecological cancers including cervical cancer. The 2024 survey of 17 radiotherapy centres found that public facilities had a mean of 0.67 brachytherapy units, while mixed facilities had a mean of 1 unit, and private facilities had none . This indicates infrastructure concentration and potential access disparities.
• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies. KFSH&RC is leading innovation in cancer radiopharmaceuticals by locally producing essential radionuclides such as iodine-123 and gallium-67 . The SFDA has established specific requirements for importing radioactive medical materials, including technical and clinical specification approval .

Saudi Arabia Radiotherapy Market By Offering
• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by high capital costs and sustained government investment. Saudi Arabia is completely import-dependent for teletherapy machines, with no domestic manufacturing capability . A standard single-energy linear accelerator with IGRT capabilities typically costs USD 2.0–3.5 million, while dual-energy systems with stereotactic features command USD 3.5–5.0 million . Compact proton therapy systems can exceed USD 15–25 million inclusive of building-integrated shielding and installation . Total project costs, including bunker construction and shielding, add 40–60% to the base equipment price .
• Software & Services: This is the fastest-growing segment, reflecting increasing digitalisation of radiation oncology and the need for lifecycle management. Service contract pricing follows a standard range of 10–15% of equipment value per year, with escalation clauses tied to local labour costs and parts availability . Competitive dynamics centre on clinical workflow integration, uptime guarantees, and training support rather than price alone . Regional distribution partners, such as Al-Mofida Medical Equipment Co., handle logistics, customs clearance, and after-sales service .

Saudi Arabia Radiotherapy Market By Application
• Breast Cancer: This is the largest application segment, with breast cancer one of the most prevalent and treated cancers in Saudi Arabia . The proactive approach of the Saudi healthcare system in promoting breast cancer awareness and screening programmes has led to earlier detection and diagnosis, resulting in more effective treatment outcomes with radiotherapy playing a pivotal role . The JHAH Oncology Center of Excellence specialises in breast cancer treatment .
• Prostate Cancer: A significant application area, with JHAH's Oncology Center of Excellence specialising in prostate cancer alongside breast and colorectal cancers . EBRT is widely utilised for prostate cancer treatment across the Kingdom.
• Colorectal Cancer: A significant application area, with JHAH's Oncology Center of Excellence specialising in colorectal cancer . Radiotherapy plays a role in neoadjuvant and adjuvant treatment.
• Lung Cancer: A growing application segment, with advanced radiotherapy techniques being adopted across Saudi healthcare facilities . The Saudi Proton Therapy Centre is equipped to treat lung cancer and other complex cases .
• Head & Neck Cancer: This is a critical application requiring highly conformal radiation delivery. Proton therapy offers significant advantages for head and neck cancers by reducing dose to adjacent critical structures .
• Paediatric Cancers: Proton therapy is especially effective for paediatric cancers, as it reduces long-term side effects and protects healthy tissue during child development . The Saudi Proton Therapy Centre is equipped for paediatric oncology .
• Central Nervous System / Brain: A significant application area, with proton therapy particularly beneficial for brain tumours and CNS tumours .

Saudi Arabia Radiotherapy Market By End User
• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, operating within the public healthcare system. A 2024 survey found public facilities operated a mean of 2.1 LINACs and treated a mean of 911 patients annually . Major centres include King Faisal Specialist Hospital and Research Centre, King Fahd Medical City (Saudi Proton Therapy Centre), and Johns Hopkins Aramco Healthcare . These institutions manage the most complex equipment fleets and are the primary beneficiaries of government investment programmes.
• Standalone Radiotherapy Centres: This segment includes private and mixed facilities. Private facilities operated a mean of 1.2 LINACs and treated a mean of 254 patients annually, while mixed facilities operated a mean of 5 LINACs and treated a mean of 2,141 patients annually . The Batik-X radiation therapy centre in Riyadh, which received the first Halcyon system in Saudi Arabia, represents private sector investment .
• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in clinical research and technology validation. KFSH&RC is leading innovation in CAR-T cell therapy, CRISPR gene editing, and radiopharmaceuticals . The collaboration between RaySearch Laboratories and C-RAD in May 2024 to develop innovative radiotherapy solutions demonstrates the research focus in the Kingdom .

Saudi Arabia Radiotherapy Market Economics


• Equipment procurement in Saudi Arabia is entirely import-based, with no domestic manufacturing capability for teletherapy machines . Standard single-energy linear accelerators with IGRT capabilities range from USD 2.0–3.5 million; dual-energy systems with stereotactic features range from USD 3.5–5.0 million; stereotactic radiosurgery platforms range from USD 4.5–7.0 million; and compact proton therapy systems can exceed USD 15–25 million inclusive of installation .
• Total project costs, including bunker construction, shielding, treatment-planning software, and patient positioning systems, add 40–60% to the base equipment price . Tariff treatment under the GCC Customs Union generally applies a 0–5% duty rate .
• Service contract pricing follows a standard range of 10–15% of equipment value per year, with escalation clauses tied to local labour costs and parts availability . Competitive dynamics centre on clinical workflow integration, uptime guarantees, and training support .
• The Saudi Proton Therapy Centre represents one of the largest health sector investments at a cost exceeding SR 924 million (approximately USD 246 million) . The centre aims to treat about 1,700 patients annually, eliminating the need for patients to travel abroad for proton therapy .
• Workforce constraints present economic challenges. The 2024 survey found that public and private sector disparities may undermine equitable access to radiotherapy services, with waiting times for radical treatment in public centres requiring policy attention . Training gaps across many centres suggest the need for coordinated national CPD programmes .
• Cost drivers include global supply-chain concentration among three dominant linear accelerator manufacturers, currency fluctuations, and input-cost escalation for high-power microwave components, precision-machined gantry assemblies, and semiconductor-based imaging detectors .

Market Outlook by Infrastructure, Investment and Industry Development


• The Saudi Proton Therapy Centre at King Fahd Medical City, the first and only proton beam therapy facility in the Middle East, is fully operational. Established on 4,000 square metres at a cost exceeding SR 924 million, the centre features a cyclotron, beam transport system, rotating gantry, five treatment rooms, CT simulation, and radiation planning systems .
• Johns Hopkins Aramco Healthcare unveiled plans for an Oncology Center of Excellence in Riyadh in October 2025, specialising in breast, colorectal, and prostate cancers . The centre will provide comprehensive, patient-centric care and represents the Kingdom's commitment to world-class oncology services.
• King Faisal Specialist Hospital and Research Centre is leading innovation in cancer radiopharmaceuticals by locally producing essential radionuclides, reducing reliance on imports . KFSH&RC is also pioneering CAR-T cell therapy and CRISPR gene editing for cancer treatment .
• Technology modernisation is advancing through partnerships between global and local companies. Varian installed the first Halcyon system in Saudi Arabia at the Batik-X radiation therapy centre in Riyadh in April 2024 . RaySearch Laboratories and C-RAD signed a collaboration agreement in May 2024 to develop innovative radiotherapy solutions .
• Strategic partnerships are expanding treatment options. In May 2025, ImmunityBio signed a MoU with MISA, KFSH&RC, and KAIMRC to launch the "Cancer BioShield" immunotherapy platform in the Middle East, integrating cell therapy and radiotherapy . In July 2025, CEL-SCI Corporation announced a partnership for commercialisation of Multikine immunotherapy for head and neck cancer .
• Workforce development is a critical priority. A 2024 study identified that training gaps across many centres suggest the need for coordinated national continuing professional development programmes to support safe implementation of advanced technologies . The study's findings provide timely evidence to inform outsourcing initiatives, strategic planning, policy development, and investment decisions .
• The long-term outlook remains positive as cancer rates in the GCC region are projected to rise by over 140% between 2020 and 2040 . Sustained government investment through Vision 2030, the expansion of proton therapy capabilities, and strategic partnerships with global institutions position Saudi Arabia as a regional hub for specialised cancer care .



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Radiotherapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• External Beam Radiotherapy (EBRT)
• Internal / Brachytherapy
• Systemic Radiotherapy

By Offering
• Radiotherapy Systems/Equipment
• Software & Services

By Application
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Head & Neck Cancer
• Central Nervous System / Brain
• Gastro-intestinal
• Other Applications

By End User

• Hospitals & Integrated Cancer Centers
• Standalone Radiotherapy Centers
• Academic/Research Institutions
• Other Healthcare Facilities

Table of Contents

  • 1. Executive Summary
  • 2. Market Structure
  • 2.1. Market Considerate
  • 2.2. Assumptions
  • 2.3. Limitations
  • 2.4. Abbreviations
  • 2.5. Sources
  • 2.6. Definitions
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Saudi Arabia Geography
  • 4.1. Population Distribution Table
  • 4.2. Saudi Arabia Macro Economic Indicators
  • 5. Market Dynamics
  • 5.1. Key Insights
  • 5.2. Recent Developments
  • 5.3. Market Drivers & Opportunities
  • 5.4. Market Restraints & Challenges
  • 5.5. Market Trends
  • 5.6. Supply chain Analysis
  • 5.7. Policy & Regulatory Framework
  • 5.8. Industry Experts Views
  • 6. Saudi Arabia Radiotherapy Market Overview
  • 6.1. Market Size By Value
  • 6.2. Market Size and Forecast, By Therapy Type
  • 6.3. Market Size and Forecast, By Offering
  • 6.4. Market Size and Forecast, By Application
  • 6.5. Market Size and Forecast, By End User
  • 6.6. Market Size and Forecast, By Region
  • 7. Saudi Arabia Radiotherapy Market Segmentations
  • 7.1. Saudi Arabia Radiotherapy Market, By Therapy Type
  • 7.1.1. Saudi Arabia Radiotherapy Market Size, By External Beam Radiotherapy (EBRT), 2020-2031
  • 7.1.2. Saudi Arabia Radiotherapy Market Size, By Internal / Brachytherapy, 2020-2031
  • 7.1.3. Saudi Arabia Radiotherapy Market Size, By Systemic Radiotherapy, 2020-2031
  • 7.2. Saudi Arabia Radiotherapy Market, By Offering
  • 7.2.1. Saudi Arabia Radiotherapy Market Size, By Radiotherapy Systems/Equipment, 2020-2031
  • 7.2.2. Saudi Arabia Radiotherapy Market Size, By Software & Services, 2020-2031
  • 7.3. Saudi Arabia Radiotherapy Market, By Application
  • 7.3.1. Saudi Arabia Radiotherapy Market Size, By Breast Cancer, 2020-2031
  • 7.3.2. Saudi Arabia Radiotherapy Market Size, By Prostate Cancer, 2020-2031
  • 7.3.3. Saudi Arabia Radiotherapy Market Size, By Lung Cancer, 2020-2031
  • 7.3.4. Saudi Arabia Radiotherapy Market Size, By Head & Neck Cancer, 2020-2031
  • 7.3.5. Saudi Arabia Radiotherapy Market Size, By Central Nervous System / Brain, 2020-2031
  • 7.3.6. Saudi Arabia Radiotherapy Market Size, By Gastro-intestinal, 2020-2031
  • 7.3.7. Saudi Arabia Radiotherapy Market Size, By Other Applications, 2020-2031
  • 7.4. Saudi Arabia Radiotherapy Market, By End User
  • 7.4.1. Saudi Arabia Radiotherapy Market Size, By Hospitals & Integrated Cancer Centers, 2020-2031
  • 7.4.2. Saudi Arabia Radiotherapy Market Size, By Standalone Radiotherapy Centers, 2020-2031
  • 7.4.3. Saudi Arabia Radiotherapy Market Size, By Academic/Research Institutions, 2020-2031
  • 7.4.4. Saudi Arabia Radiotherapy Market Size, By Other Healthcare Facilities, 2020-2031
  • 7.5. Saudi Arabia Radiotherapy Market, By Region
  • 7.5.1. Saudi Arabia Radiotherapy Market Size, By North, 2020-2031
  • 7.5.2. Saudi Arabia Radiotherapy Market Size, By East, 2020-2031
  • 7.5.3. Saudi Arabia Radiotherapy Market Size, By West, 2020-2031
  • 7.5.4. Saudi Arabia Radiotherapy Market Size, By South, 2020-2031
  • 8. Saudi Arabia Radiotherapy Market Opportunity Assessment
  • 8.1. By Therapy Type, 2026 to 2031
  • 8.2. By Offering, 2026 to 2031
  • 8.3. By Application, 2026 to 2031
  • 8.4. By End User, 2026 to 2031
  • 8.5. By Region, 2026 to 2031
  • 9. Competitive Landscape
  • 9.1. Porter's Five Forces
  • 9.2. Company Profile
  • 9.2.1. Company 1
  • 9.2.1.1. Company Snapshot
  • 9.2.1.2. Company Overview
  • 9.2.1.3. Financial Highlights
  • 9.2.1.4. Geographic Insights
  • 9.2.1.5. Business Segment & Performance
  • 9.2.1.6. Product Portfolio
  • 9.2.1.7. Key Executives
  • 9.2.1.8. Strategic Moves & Developments
  • 9.2.2. Company 2
  • 9.2.3. Company 3
  • 9.2.4. Company 4
  • 9.2.5. Company 5
  • 9.2.6. Company 6
  • 9.2.7. Company 7
  • 9.2.8. Company 8
  • 10. Strategic Recommendations
  • 11. Disclaimer

Table 1: Population Distribution, 2025
Table 2: Economic Snapshot, 2025
Table 3: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 4: Influencing Factors for Radiotherapy Market, 2025
Table 5: Saudi Arabia Radiotherapy Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Million)
Table 6: Saudi Arabia Radiotherapy Market Size and Forecast, By Offering (2020 to 2031F) (In USD Million)
Table 7: Saudi Arabia Radiotherapy Market Size and Forecast, By Application (2020 to 2031F) (In USD Million)
Table 8: Saudi Arabia Radiotherapy Market Size and Forecast, By End User (2020 to 2031F) (In USD Million)
Table 9: Saudi Arabia Radiotherapy Market Size and Forecast, By Region (2020 to 2031F) (In USD Million)
Table 10: Saudi Arabia Radiotherapy Market Size of External Beam Radiotherapy (EBRT) (2020 to 2031) in USD Million
Table 11: Saudi Arabia Radiotherapy Market Size of Internal / Brachytherapy (2020 to 2031) in USD Million
Table 12: Saudi Arabia Radiotherapy Market Size of Systemic Radiotherapy (2020 to 2031) in USD Million
Table 13: Saudi Arabia Radiotherapy Market Size of Radiotherapy Systems/Equipment (2020 to 2031) in USD Million
Table 14: Saudi Arabia Radiotherapy Market Size of Software & Services (2020 to 2031) in USD Million
Table 15: Saudi Arabia Radiotherapy Market Size of Breast Cancer (2020 to 2031) in USD Million
Table 16: Saudi Arabia Radiotherapy Market Size of Prostate Cancer (2020 to 2031) in USD Million
Table 17: Saudi Arabia Radiotherapy Market Size of Lung Cancer (2020 to 2031) in USD Million
Table 18: Saudi Arabia Radiotherapy Market Size of Head & Neck Cancer (2020 to 2031) in USD Million
Table 19: Saudi Arabia Radiotherapy Market Size of Central Nervous System / Brain (2020 to 2031) in USD Million
Table 20: Saudi Arabia Radiotherapy Market Size of Gastro-intestinal (2020 to 2031) in USD Million
Table 21: Saudi Arabia Radiotherapy Market Size of Other Applications (2020 to 2031) in USD Million
Table 22: Saudi Arabia Radiotherapy Market Size of Hospitals & Integrated Cancer Centers (2020 to 2031) in USD Million
Table 23: Saudi Arabia Radiotherapy Market Size of Standalone Radiotherapy Centers (2020 to 2031) in USD Million
Table 24: Saudi Arabia Radiotherapy Market Size of Academic/Research Institutions (2020 to 2031) in USD Million
Table 25: Saudi Arabia Radiotherapy Market Size of Other Healthcare Facilities (2020 to 2031) in USD Million
Table 26: Saudi Arabia Radiotherapy Market Size of North (2020 to 2031) in USD Million
Table 27: Saudi Arabia Radiotherapy Market Size of East (2020 to 2031) in USD Million
Table 28: Saudi Arabia Radiotherapy Market Size of West (2020 to 2031) in USD Million
Table 29: Saudi Arabia Radiotherapy Market Size of South (2020 to 2031) in USD Million

Figure 1: Saudi Arabia Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Million)
Figure 2: Market Attractiveness Index, By Therapy Type
Figure 3: Market Attractiveness Index, By Offering
Figure 4: Market Attractiveness Index, By Application
Figure 5: Market Attractiveness Index, By End User
Figure 6: Market Attractiveness Index, By Region
Figure 7: Porter's Five Forces of Saudi Arabia Radiotherapy Market

Saudi Arabia Radiotherapy Market Research FAQs

The Middle East & Africa Radiotherapy Market is anticipated to grow at more than 8.6% CAGR from 2026 to 2031, driven by rising cancer incidence, with over 1 million new cancer cases reported annually in Africa, sustained government investment in healthcare infrastructure, and international initiatives expanding access to radiotherapy services.

Saudi Arabia dominates the Middle East radiotherapy market, supported by substantial government investment in healthcare infrastructure, with the Saudi Proton Therapy Centre at King Fahad Medical City representing the first cancer treatment centre in the Middle East using proton therapy.

Key drivers include rising cancer burden, with cancer now among the leading causes of premature mortality in Africa, sustained government investment in advanced radiotherapy infrastructure, including proton and heavy-ion therapy centres in Saudi Arabia and the UAE, and international initiatives such as the IAEA's Rays of Hope initiative expanding access to radiotherapy services.

Proton Beam Therapy is the fastest-growing technology segment in the Middle East, driven by the expansion of proton therapy infrastructure in Saudi Arabia, the UAE, and Egypt, alongside significant government investment and clinical evidence supporting its use for paediatric cancers, brain tumours, and head and neck cancers.

Breast cancer is the largest application segment in the Middle East & Africa Radiotherapy Market, driven by more than 130,000 new breast cancer cases recorded annually in the Middle East and the high prevalence of breast cancer across Africa, where it is among the most frequently diagnosed cancers.

Systemic radiotherapy is the fastest-growing therapy segment, fueled by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies, with the IAEA supporting the development of nuclear medicine capabilities across the region.

Key challenges include severe infrastructure deficits, with more than 20 African countries having no radiotherapy machine, workforce shortages and training gaps, and significant regional disparities in equipment distribution and access to radiotherapy services.

The long-term outlook remains positive as cancer incidence continues to rise, sustained government and international investment drives equipment modernisation and infrastructure expansion, and the IAEA's Rays of Hope initiative continues to support capacity building. However, addressing severe infrastructure deficits, workforce constraints, and regional disparities will be essential to ensuring equitable access to radiotherapy services across all countries in the Middle East & Africa region.
Logo

Saudi Arabia Radiotherapy Market Overview, 2031

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Claude Summarize

Contact usWe are friendly and approachable, give us a call.